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A Non–Gas-Based Cryotherapy System for the Treatment of
Cervical Intraepithelial Neoplasia: A Mixed-Methods
Approach for Initial Development and Testing
Miriam Cremer,a,b Proma Paul,b,c Katie Bergman,b Michael Haas,d,e Mauricio Maza,b Albert Zevallos,f
Miguel Ossandon,g Jillian D Garai,b Jennifer L Winklerb,h
A non–gas-based treatment device for early cervical cancer treatment, adapted for use in low-resource settings
to improve ease of use, portability, and durability, performed similarly to a standard gas-based cryotherapy
device in small-scale testing. A large randomized clinical trial is currently underway for further assessment.
ABSTRACT
Background: Gas-based cryotherapy is the most widely used treatment strategy for cervical intraepithelial neoplasia
(CIN) in low-resource settings, but reliance on gas presents challenges in low- and middle-income countries (LMICs).
Our team adapted the original CryoPen Cryosurgical System, a cryotherapy device that does not require compressed
gas and is powered by electricity, for use in LMICs.
Methods: A mixed-methods approach was used involving both qualitative and quantitative methods. First, we used a
user-centered design approach to identify priority features of the adapted device. U.S.-based and global potential users
of the adapted CryoPen participated in discussion groups and a card sorting activity to rank 7 features of the adapted
CryoPen: cost, durability, efficacy and safety, maintenance, no need for electricity, patient throughput, and portability.
Mean and median rankings, overall rankings, and summary rankings by discussion group were generated. In addition,
results of several quantitative tests were analyzed including bench testing to determine tip temperature and heat extraction
capabilities; a pathology review of CIN grade 3 cases (N=107) to determine target depth of necrosis needed to achieve
high efficacy; and a pilot study (N=5) investigating depth of necrosis achieved with the adapted device to assess efficacy.
Results: Discussion groups revealed 4 priority themes for device development in addition to the need to ensure high efficacy
and safety and low cost: improved portability, durability, ease of use, and potential for cure. Adaptions to the original CryoPen
system included a single-core, single-tip model; rugged carrying case; custom circuit to allow car battery charging; and ster-
ilization by high-level disinfection. In bench testing, there were no significant differences in tip temperature or heat extraction
capability between the adapted CryoPen and the standard cryotherapy device. In 80% of the cases in the pilot study, the
adapted CryoPen achieved the target depth of necrosis 3.5 mm established in the pathology review.
Conclusion: The LMIC-adaptedCryoPen overcomes barriers to standardgas-based cryotherapy by eliminatingdependency
on gas, increasing portability, and ensuring consistent freeze temperatures. Further testing and evaluation of the adapted
CryoPen will be pursued to assess scalability and potential impact of this device in decreasing the cervical cancer burden in
LMICs.
BACKGROUND
Cervical cancer continues to be a global public healthproblem, with the greatest disease burden in low-
and middle-income countries (LMICs).1 The number of
women screened for cervical cancer has increased in
many countries over the past decade.2 However, screen-
ingmust be linkedwith effective, affordable treatment in
order to achieve a reduction in cervical cancer incidence
and mortality.
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Gas-based cryotherapy is themost widely used
treatment strategy for cervical intraepithelial neo-
plasia (CIN) in low-resource settings. This ablative
technique uses compressed carbon dioxide or
nitrous oxide gas to freeze lesions, resulting in
necrosis of cells. Although gas-based cryotherapy
is safe, simple, and generally inexpensive, chal-
lenges include difficulties with procuring gas,
transporting and refilling gas tanks, and providing
treatment in high-volume settings.3–5 A standard-
size gas tank has the capacity to provide treatment
for only 3 patients, while a large tank can treat
more women but is difficult to transport from
clinic to clinic.6
Innovative new technologies offer treat-
ment alternatives. For example, the CryoPen
Cryosurgical System is a novel cryotherapy
technology that does not require compressed
gas and is powered by electricity. The CryoPen
reaches extreme cold temperatures with use of a
Stirling Cryocooler that chills the core to opera-
tional temperatures of 105°C. Between treat-
ments, the core rests in the chilling well filled
with an ounce of ethanol or grain alcohol, which
facilitates heat transfer. The CryoPen was origi-
nally designed to treat dermatologic conditions
and was modified for gynecologic use in 2011. It
is currently approved by the U.S. Food and Drug
Administration (FDA) for CIN grade 2 and more
severe (CIN2þ) diagnoses.
The original CryoPen device, however, is not
conducive for use in LMICs. Our team of clinicians
and biomedical engineers collaborated to develop
an LMIC-adapted CryoPen optimized for use
in low-resource settings. To design the LMIC-
adapted CryoPen prototype, we sought guidance
on features thatwouldmeet the needs of clinicians
interested in using this technology in LMICs. We
followed a user-centered design approach to
better understand current cryotherapy methods
in LMICs, features that would be essential in an
LMIC-adapted CryoPen, advantages and disad-
vantages of the initial prototype, and factors that
may facilitate adoption of the adapted device.
To ensure that the LMIC-adapted CryoPen is
non–inferior to standard cryotherapy devices, we
performed in vitro studies using ballistic gelatin
and the double-freeze approach recommended by
the World Health Organization to determine the
prototype’s tip temperature and heat extraction
capabilities.7 A pilot study was performed using
an exploratory single-freeze approach to compare
the depth of necrosis achieved by the LMIC-
adapted CryoPen and CO2-based cryotherapy in
healthy cervical tissue.
The purpose of this article is to describe the
design approach and device adaptations of the
LMIC-adapted CryoPen and to report initial clini-
cal data.
MATERIALS AND METHODS
Qualitative Methods: Experiences With
Cryotherapy and Device Perceptions
Using a convenience sample, we held 3 focus
group discussion sessions with key stakeholders
and potential users of the LMIC-adapted CryoPen.
Verbal consent to participate was obtained prior to
the discussions. None of the participants were
compensated for their participation in anyway.
During the first session, at CryoPen, Inc. head-
quarters in September 2014, 10 cervical cancer
prevention stakeholders met to discuss the devel-
opment of the LMIC-adapted CryoPen. Two
additional discussion sessions were held in con-
junction with the Global Academic Partnership
(GAP) conference in Houston, Texas, in April
2015. Most of the stakeholders who participated
in the September discussion session participated
in the second session. From the larger group
of GAP conference attendees, we identified partic-
ipants who worked in cervical cancer prevention
globally and invited them to join the third
discussion session. This third group consisted of
22 potential users or key stakeholders from
Brazil, China, Colombia, India, Mexico, South
Africa, Thailand, and Zambia, as well as U.S.
participants who have performed cryotherapy in
Guatemala and Peru. The stakeholders were all
experienced in cervical cancer prevention and
included trainers or practitioners in visual inspec-
tion with acetic acid (VIA) and cryotherapy, a
cryotherapist, a colposcopist, gynecologic oncolo-
gists, a pathologist, a radiologist, and a registry
and cervical cancer prevention program planner.
During the second and third discussion ses-
sions, the participants used a card sorting activity
to rank 7 features of the LMIC-adapted CryoPen
and then discussed the potential design trade-offs
in various settings. Participants described their
experiences with cryotherapy and shared feed-
back on the LMIC-adapted CryoPen prototype.
Digital recordings and field notes were
reviewed using an iterative content analysis
approach for qualitative analysis to identify
emerging themes. Key quotes were transcribed to
illustrate identified themes. We calculated a mean
and median ranking for each feature included in
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ranking for each feature as well as a summary
ranking for each by discussion group.
The University of Pittsburgh Institutional
Review Board (IRB) determined that the focus
group discussions qualified as non–research.
Quantitative Methods: Device Testing
Bench Testing
Bench testing of the LMIC-adapted CryoPen and
a standard cryotherapy device, the N2O-based
Wallach LL100 System, was performed in the
Basic Health International laboratory in San
Salvador, El Salvador. The office lab has the
capacity to maintain consistent room temperature
and humidity, which provided controlled testing
between trials. No animals or hazardous materials
were used in testing. An engineer who graduated
from the ABET-accredited bioengineering pro-
gram at Rice University conducted the bench tests.
For comparative studies of the tip temperature
and heat extraction capabilities of the 2 devices,
ballistic gelatin was used as the cervical tissue
analogue. It is not a perfect surrogate, but the
bias is the same for all devices that were tested.
Ballistic gelatin, composed of gelatin powder
and water, is FDA-cleared to test gynecologic
ablation devices such as the Her Option Uterine
Cryoblation Therapy System (PMA Number
P000032). Standard procedure was followed for
preparing ballistic gelatin samples for testing. The
starting temperature of the gelatin samples was
room temperature. A custom jig was designed to
perform freezing tests on ballistic gelatin using
the CryoPen Cryosurgical System (both standard
and prototype LMIC-adapted models). Fifteen
trials were conducted with each device using a
double-freeze approach consisting of a 3-minute
freeze, followed by a 5-minute thaw, and a second
3-minute freeze (3’–5’–3’), which is the recom-
mended treatment approach per the most
recent World Health Organization guidelines for
cryotherapy.7
Heat extraction capabilities were measured in
terms of mass of the freeze ball and the lateral
freeze and depth of freeze dimensions. At the
completion of the 3’–5’–3’ freeze cycle, the freeze
ball was excised from the gelatin. Excess gelatin
was removed from the freeze ball before the mass
was recorded on a scale. After the freeze ball
mass was recorded, the lateral freeze and depth of
freeze dimensions were recorded using calipers.
Fifteen tests of each set of data points were
performed to ensure data collection replication.
Copper-constantan thermocouples and an Omega
Instruments Data Acquisition system were used
to collect temperature data.8
Pathology Review to Determine Target Depth
of Necrosis
We investigated the depth of CIN in order to
determine target depth of necrosis required for
high efficacy of the device. A study of the depth
of CIN1–3 by Abdul-Karim showed a depth of
necrosis of 3.5 mm is needed to treat 95% of
CIN1–3 lesions and a depth of 4.8 mm is needed
to treat 99% of all cases.9 With our collaborators
at the National Institute for Neoplastic Diseases
(INEN) in Peru, our group analyzed 107 con-
firmed cases of CIN3 in cold knife cone biopsy
specimens from an under-screened population.
Two expert pathologists reviewed slides of
previously confirmed cases of CIN3. INEN and
Cleveland Clinic granted IRB approval.
Depth of CIN3 ranged from 0.2mm to 6.9mm,
with a mean of 2.0 mm. Overall, 85/107 (79.4%)
had a depth <3.0 mm, 96/107 (89.7%) had a
depth <3.5 mm, 100/107 (93.5%) had a depth
<4.0 mm, and 100/107 (93.5%) had a depth
<5.0 mm. Using these findings and Abdul-
Karim’s conclusion that a depth of 3.5 mm is
needed to treat 95% of CIN2þ lesions, we deter-
mined that our clinical goal was to achieve a
minimum depth of necrosis of 3.5 mm in at least
80% of cases. Since cryotherapy is approximately
80% effective in treating CIN, we set 80% as the
goal in order to determine equivalence.
Pilot Study to Determine Depth of Necrosis Achieved
With LMIC-Adapted CryoPen
A pilot study (N=5) was then conducted to deter-
mine if the LMIC-adapted CryoPen achieved a
depth of necrosis of 3.5 mm in women with
healthy cervical tissue. Women aged 21–64 years
who presented at INEN for hysterectomy indi-
cated by conditions unrelated to cervical pre-
cancer or cervical cancer were invited to
participate. Women did not receive any financial
incentive to participate. IRB approval for the pilot
study was granted by both INEN and Cleveland
Clinic.
Five women were treated with a single
5-minute (5’) freeze application of the LMIC-
adapted CryoPen; the straightforward 5’ freeze
was chosen so that providers could become
comfortable with the device. The participants
then underwent their prescheduled hysterectomy
24 hours after treatment, and cervical tissue was
processed to allow evaluation of depth of necrosis
caused by ablation. The entire cervix obtained
Our clinical goal
was to achieve a
minimumdepth of
necrosis of 3.5mm
in at least 80% of
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from the hysterectomy procedures was detached
from the uterus and cut at 3 and 9 o’clock posi-
tions to separate the anterior and posterior lips.
Both pieces of tissue were fixed in formalin for
24 hours. Multiple serial sections of specimens
were obtained from each of the cervical lips.
The pathologists evaluating the cervical speci-
mens were blinded to which device was used to
perform the ablative treatment. Microscopic eval-
uation of depth of necrosis was conducted by
superimposing a micrometer in the 10x eyepiece.
Multiple measurements were taken and only the
deepest area of necrosis was recorded for this
study. Determination of the deepest level of ne-
crosis was based on the observation of destruction
of the glandular epithelium in the gland crypts in





Providers in our group with experience in
Colombia, Guatemala, Peru, Thailand, and
Zambia described the context in which they use
cryotherapy for precancerous cervical lesions.
Cryotherapy is practiced broadly in Thailand and
is provided either at a health center or through a
mobile clinic. In Zambia, cryotherapy is performed
at regional health facilities; although the mobile
units maintained by the Ministry of Health could
provide cryotherapy, this is not currently prac-
ticed. In Colombia, precancerous cervical lesions
are primarily treated through excision techniques;
cryotherapy is performed only in remote counties.
Other providers in our group from Brazil, China,
and India reported using only excisional techni-
ques such as loop electrosurgical excision proce-
dure (LEEP) and had limited experience with
cryotherapy.
Device Perceptions
The card sorting activity facilitated the core con-
versation in which participants ranked the most
important features (out of 7) for a new cryother-
apy device designed for the low-resource settings
in which they practice. The 7 features and their
overall rankings are as follows:
Efficacy and safety (overall ranking 1):
While there was some variation in the ranking of
efficacy and safety, this featurewas ranked highest
overall. A participant from Zambia noted:
Efficacy and safety was the most important [feature]
because whatever new device goes into the market, it
has to be non–inferior to the current practice.
Cost (overall ranking 2): Cost was ranked ei-
ther very high or very low, but the summary rank-
ing was second overall. Participants felt that the
target price of US$4,000 for the new device was
reasonable, especially given that this device would
not require purchase of gas.
Durability and Maintenance (overall
ranking 3): Durability and maintenance, 2 sepa-
rate features, were discussed in interwoven lan-
guage. Durability was considered a core issue for
this setting. Participants defined durability in
terms of simplicity and the concept that a device
could not be broken. A participant from the
United States who has practiced broadly in low-
resource settings said:
I ranked durability first, and part of that is that I feel
like every public hospital I’ve gone to in low- and
middle-income countries, you can barely walk down
the hall because there are all these donated instruments
from the U.S. lining the halls that don’t work, that are
broken . . . You know, no one knows how to maintain
them.
Another participant who has practiced cryo-
therapy in Guatemala raised the need for simplic-
ity of design:
. . . but as you’ve shown you have the [thermo]coupler, a
microchip, a something, it sounds like there are a lot
more things that could break there than your typical
cryo unit and a nitrous tank . . . . ‘cause the only thing
that can go wrong with the [traditional] cryo gun is if
you try to use it when the pressure is too high in the tank.
Participants were supportive of simple in-
expensive maintenance, but reiterated the im-
portance of durability. Participants also acknowl-
edged that routine maintenance has generally
not been practiced with current cryotherapy
equipment.
Portability (overall ranking 4): Portability
was discussed in terms of the ability to bring a de-
vice to a remote setting. Participants felt that a
truly portable device would open up the option of
delivering cryotherapy in remote settings that are
not currently being reached because of the logisti-
cal difficulties of transporting the gas tank needed
for standard cryotherapy. A participant from
Zambia noted:
If it is not portable then it can’t get to the rural areas





in terms of desired
features of an
adapted CryoPen.
Non–Gas-Based Cryotherapy System for CIN Treatment www.ghspjournal.org
Global Health: Science and Practice 2017 | Volume 5 | Number 1 60
Patient throughput (overall ranking 5):
Participants explained that the proposed target of
each device being able to treat 15 patients per day
was acceptable, and so they saw no need to priori-
tize this issue above others. One participant
explained:
When we screen about 200–250 [patients], we only
freeze about 15 a day, that is why it was at the bottom.
No electricity (overall ranking 6): Many
sites where cryotherapy will be practiced have
electricity. Participants felt that the proposed
approach of paying an additional cost for a
modularized additional battery feature would
adequately address the need to bring the device
to remote areas that do not have electricity.
Integrating Feedback to Optimize the LMIC-Adapted
CryoPen Cryosurgical System
The device prototype was modified based on the
4 priority areas that came out of the focus group
discussions: (1) improved portability—essential
for large mobile health services that many coun-
tries rely on to treat women living in remote areas,
(2) better durability, which allows for decreased
maintenance and costs, and increases capacity for
rugged travel and use, (3) greater ease-of-use,
which simplifies operation of the device and
expands potential for use by trained providers,
and (4) enhanced potential for cure, which
ensures greater efficacy for the treatment of pre-
cancerous lesions.
The LMIC-adapted CryoPen Cryosurgical
System has several design modifications that
distinguish it from the original CryoPen (Figure
1). To increase efficacy of treatment, a single
19–20 mm conical tip was designed for the
new model. Compared with the original
model’s tip, the new larger tip size ensures
that the adapted device achieves greater cover-
age of precancerous lesions, and the anatomi-
cally correct tip shape allows for better contact
with the cervix. The original CryoPen required
a core swap mid-procedure, whereas the
LMIC-adapted CryoPen has a single core that
can be applied for a 3’–5’–3’ or a single 5’ pro-
cedure. A clear sheath, made of medical-grade
polycarbonate, increases visibility and protects
the vaginal walls. The sheath is inserted with
the attached tip positioned against the cervix;
the core is then inserted into the sheath, with
a gap preventing contact between the sheath
and core for insulation purposes.
To increase durability, the new model was
built to handle irregular currents and to withstand
physical damage in extreme conditions (ambient
temperatures of 100°C to 40°C) and from drops
up to 5 feet. In addition, the new model is easily
maintainable. The device has a removable air fil-
ter, which can be removed, cleaned, and replaced
on site. The protective sheath and attached tip are
the only components in direct contact with
human tissue and can be cleaned sufficiently with
high-level disinfection (HLD) rather than requir-
ing autoclave sterilization.
The LMIC-adapted device is portable, weigh-
ing 20 lbs., and equippedwith a handle. To address
focus group participants’ interest in a modularized
approach to a battery feature, a custom circuit was
designed to allow the LMIC-adapted CryoPen to
run via car batteries for use in settings without
another source of electricity.
Quantitative Results: Device Testing
Results of Bench Testing
The results of the 15 bench test trials showed that
the LMIC-adapted CryoPen achieved equivalent
depth of freeze, depth of lateral freeze, diameter
of freeze, and mass of freeze ball compared with
the Wallach LL100 (Table 1). The minimum tip
temperatures reached by both devices and the
average of the temperatures reached during the
2 freezes were also equivalent. There were no
significant differences between devices in any
FIGURE 1. Standard CryoPen System Available in the United
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tip temperature or heat extraction capability
measurements.
Depth of Necrosis Pilot Study
Average maximum depth of necrosis in the ante-
rior lip was 4.12 mm (standard deviation [SD],
1.49 mm), and average maximum depth in
the posterior lip was 4.08 mm (SD, 1.05 mm)
(Table 2). A depth of necrosis of 3.5 mm was
achieved in 80% of the samples (maximum depth
of necrosis was ≥4.0 mm in 80% of cases).
DISCUSSION
Despite the continued need for secondary preven-
tion of cervical cancer via treatment of precancer-
ous lesions, there have been few efforts to develop
treatment devices tailored to the specific chal-
lenges and needs of LMICs. In developing the
LMIC-adapted CryoPen cryotherapy treatment
device, each adaptation was made specifically to
optimize utility in low-resource settings while
maintaining high efficacy and safety. The user-
centered design approach used in this study was
an effective way to solicit input about important
features to potential users and helped inform de-
velopment of the CryoPen technology for LMIC
settings.
Participants were enthusiastic about the
potential of a non–gas-based cryotherapy device.
The LMIC-adapted CryoPen overcomes barriers
to standard gas-based cryotherapy by eliminating
dependency on gas, increasing mobility, and
ensuring consistent freeze temperatures without
blockages; the device can perform 3 procedures
per hour when connected to an electrical source.
Participants emphasized that durability and sim-
plicity were important factors, highlighting the
need for the new device to survive being
moved frequently from one location to another
in hot environments without requiring inten-
sive maintenance. Product life, which remains
unknown despite promising durability, was
therefore also an outstanding concern. With
these concerns in mind, the LMIC-adapted
CryoPen was designed with intention to enhance
3 key features:
1. Durability/Maintenance. Features include
the ability to handle irregular currents; with-
stand physical damage in extreme tempera-
tures; tolerate drops from 5 feet; be cleaned
by HLD; and be maintained easily with a
removable air filter.
2. Portability. Features include a lightweight
device; a carrying case with handle; and the
ability to run on 2 car batteries in series when
electricity is unavailable.
3. Ease-of-use. Features include a single-tip,
single-core device; a clear sheath for increased
visibility and safety; and a device amenable to
one-handed operation.
Safety and efficacy were the most important
features to participants, as introducing this tech-
nology to the current treatment paradigm will
require non–inferiority to current practice. We
ensured non–inferiority in safety and efficacy to
the current standard, gas-based cryotherapy, by
conducting bench testing of the LMIC-adapted
TABLE 1. Bench Testing Results Comparing Heat Extraction Capabilities and Tip Temperatures of






Mean (SD) Mean (SD) P Value
Depth of freeze, mm 7.14 (1.00) 6.33 (1.21) .06
Lateral depth of freeze, mm 7.86 (0.96) 7.93 (1.32) .88
Diameter of freeze, mm 29.37 (2.09) 30.71 (3.61) .23
Mass of freeze ball, g 7.71 (1.16) 8.27 (1.33) .22
Average tip temperature in freeze cycle, °C 51.84 (4.99) 48.28 (6.37) .10
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CryoPen and through a clinical trial pilot deter-
mining the depth of necrosis the device achieved
in healthy cervical tissue. The average tip temper-
ature of both freezes (51.84°C) reached by the
device is in a range theoretically capable of
destroying cervical tissue.10–12 The LMIC-adapted
CryoPen achieved equivalent heat extraction
capabilities, including depth of freeze, lateral
depth of freeze, and mass of freeze ball, compared
with the standard Wallach LL100. During the
clinical trial pilot, the LMIC-adapted CryoPen
achieved a depth of necrosis of at least 3.5 mm in
80% of cases, demonstrating the promising effi-
cacy of the device. Given the consistent perform-
ance in bench testing, the freeze that performed
less well in the clinical trial pilot may be attribut-
able to the process of clinicians adjusting to the
new technology in a clinical setting. The sample
size of the pilot study was small. A large random-
ized clinical trial that will more fully investigate
safety and efficacy issues is currently underway;
the results of this trial will have greater precision
than the pilot.
Despite the advantages presented by the
LMIC-adapted CryoPen, there are several limita-
tions associated with the device. The $4,000 cost,
although within the range deemed reasonable by
focus group participants, is more expensive than
a gas-based system ($2,000). This is a significant
investment for areas with limited funding.
However, the initial capital cost of the device is
mitigated by the elimination of ongoing gas
expenses for clinics. Depending on frequency of
use, the cost difference between the LMIC-
adapted CryoPen and a gas-based system would
be negligible within 6–18 months of use.
We recognize that costs are entailed by the
device’s electricity requirement, but we believe
that even with this constraint the LMIC-adapted
CryoPen will be more affordable than conven-
tional cryotherapy. In cost-effectiveness analy-
sis, a health economist will account for both
sources of electricity that can be utilized by the
device—alternating current supplied by an elec-
trical grid and car batteries.
The LMIC-adapted CryoPen was designed to
be simple and user-friendly, but there are steps
that must be followed during use. These include
filling the chilling well with ethanol; ensuring
that the green indicator light is on before begin-
ning treatment; and wiping condensation from
the core before reinserting it into the holding
well. These steps are simple, but they are unique
to this device and essential for proper functioning.
As with introducing any new device, proper train-
ing and repeated use will address these concerns.
An instruction booklet and video are available for
reference.
Although the device does not require N2O or
CO2, ethanol is needed to prevent the core from
freezing to the well in which it rests between pro-
cedures. Manufacturer-approved ethanol is rela-
tively easy to find and inexpensive; if unavailable,
ethanol can be substituted with grain alcohol such
as Everclear. A small bottle can facilitate hundreds
of treatments. It will nonetheless be important
that procurement systems include ethanol for use
with this device.
Further testing and evaluation of the LMIC-
adapted CryoPen should be pursued to assess scal-
ability and potential impact of this device. Despite
introduction of the prophylactic human papillo-
mavirus (HPV) vaccine, generations of unvacci-
nated women will still need to be screened and
treated for cervical precancer. In the 3 decades it
may take to implement primary prevention of cer-
vical cancer by HPV vaccine globally, an estimated
20 million more women will be diagnosed with
cervical cancer in LMICs.13 If improvements in
secondary prevention—including greater utility
of treatment devices in low-resource areas—are
not pursued, more than 250,000 women will con-
tinue to die annually from a preventable disease.
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